Notícias

GlobalData on MSN4dia(s)
Gilead hit with FDA clinical hold for batch of HIV trials
Decreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.
BioSpace5dia(s)
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline
Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD ...
US FDA pauses Gilead trials testing experimental HIV pill combination
The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
Fierce Biotech5dia(s)
FDA slaps clinical hold on multiple Gilead HIV combo therapy trials, shares fall
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...
US FDA places clinical hold on Gilead trials testing HIV pill combination
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...
Gilead: FDA Places Clinical Hold on HIV Treatment Trials of GS-1720, GS-4182
Analysts at Citi said that while the clinical hold impacts the targeted commercial launch of the GS-1720/GS-4182 regimen, previously expected around 2029/2030, they believe the setback is minor, as it ...
Medical Dialogues5dia(s)
USFDA places clinical hold on Gilead Sciences trials testing HIV pill combination
Gilead Sciences has announced that the U.S. Food and Drug Administration has placed a clinical hold on its HIV treatment ...
MPR2dia(s)
FDA Puts Clinical Hold on Gilead’s Trials for Two HIV Drug Candidates
Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...
The Pharma Letter4dia(s)
Gilead’s HIV combo trials halted by FDA amid safety concerns
Gilead Sciences has paused five clinical trials of its investigational HIV drugs GS-1720 and GS-4182 after the American medicines regulator raised safety concerns. The once-weekly oral regimen was ...
Gilead Sciences shares hit after HIV studies placed on hold by FDA
Shares of Gilead Sciences (NASDAQ: NASDAQ:GILD) declined 4% on Tuesday after the company announced that the FDA placed clinical holds on studies of several of its HIV drugs.